PRINCETON, N.J., June 25 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that it officially launched Pravastatin Sodium 80 mg Tablets into the U.S. healthcare system.
Being the first-to-file, Ranbaxy will enjoy a 180-day exclusivity for Pravastatin 80 mg and benefit from the commercial gains during this period. The annual sales for Pravastatin 80 mg are $ 209 Mn (IMS: MAT - Dec. 2006).
“We will make Pravastatin Sodium 80 mg Tablets available to all classes of trade immediately, and our Ranbaxy Sales and Distribution Teams will be doing everything to have product in the hands of our customers as quickly as possible. We are delighted to have this product formulation as an addition to our ever expanding product portfolio of affordable generic alternatives,” said Jim Meehan, Vice President of Sales and Marketing for RPI.
Pravastatin is indicated in the treatment of primary prevention of coronary events such as in hypercholesterolemic patients without clinically evident coronary heart disease. Pravastatin is also indicated to reduce the risk of myocardial infarction, reduce the risk of undergoing myocardial revascularization procedures and reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. It is also indicated for treatment in the secondary prevention of cardiovascular events such as in patients with clinically evident coronary heart disease to reduce the risk of stroke and stroke/transient ischemic attack (TIA), and slow the progression of coronary atherosclerosis.
Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.
Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary “platform technologies”, resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.
Pravastatin is the therapeutic equivalent to the reference listed drug Pravachol(R) by Bristol Myers Squibb
CONTACTS: Charles M. Caprariello Vice President, Corporate Communications Inc. Ranbaxy Inc. (609) 720-5615 Edwige Buteau RF Binder Partners (212) 994-7517 Anuj Baveja RF Binder Partners Inc. (212) 994-7552
Ranbaxy Pharmaceuticals Inc.
CONTACT: Charles M. Caprariello, Vice President, Corporate CommunicationsInc. of Ranbaxy Inc., +1-609-720-5615; or Edwige Buteau, +1-212-994-7517,or Anuj Baveja, +1-212-994-7552, both of RF Binder Partners Inc.
Web site: http://www.ranbaxy.com//
